阿布扎比正大力押注GLP-1药物和可穿戴设备，以期将其医疗体系改造为预防性护理模式。本周，Mubadala Bio在阿联酋首都举行的未来健康峰会期间，与美国药企礼来签署协议，在当地打包和分销GLP-1药物。今年4月，阿联酋成为礼来减肥药Foundayo的第二个上市国家，也是Mounjaro的早期市场之一。
Abu Dhabi is betting big on GLP-1 drugs and wearables as it seeks to retool its healthcare system for preventive care. Mubadala Bio signed a deal with US drugmaker Eli Lilly during the Future Health Summit in the UAE capital this week to package and distribute GLP-1 drugs locally. In April, the UAE became the second country to Lilly’s weight-loss pill Foundayo, and was an early market for Mounjaro.
卫生部还与两家最热门的可穿戴设备品牌Whoop和Oura启动了研究项目。总部位于波士顿的Whoop将研究持续监测和指导是否能改善肥胖和高血压成年人的胆固醇等指标，这两者都是海湾地区持续存在的公共卫生挑战。
The Department of Health also launched research projects with two of the hottest wearables brands, Whoop and Oura. Boston-based Whoop will study whether continuous monitoring and coaching can improve markers like cholesterol in adults with obesity and hypertension, both persistent public health challenges in the Gulf.
Oura启动了“摇篮计划”（Project Cradle），这是一个为期两年的试点项目，旨在观察其智能戒指是否能预警高危妊娠中的自发性早产，并将依赖阿布扎比的临床和基因组记录。
Oura launched Project Cradle, a two-year pilot to see if its ring can flag spontaneous preterm birth in high-risk pregnancies, and will rely on Abu Dhabi’s clinical and genomic records, too.